0.37
Passage Bio Inc Borsa (PASG) Ultime notizie
Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
GM1 Gangliosidosis Market: Epidemiology, Therapies, - openPR.com
Guggenheim Adjusts Price Target for Passage Bio (PASG) | PASG Stock News - GuruFocus
Passage Bio Reports Q1 2025 Financial Results and Highlights Progress in Gene Therapy Development - MSN
Wedbush Issues Pessimistic Estimate for Passage Bio Earnings - Defense World
Gm1 Gangliosidosis Treatment Market in 2025 Detailed Study - openPR.com
Passage Bio, Inc. (NASDAQ:PASG) Shares Acquired by Tower Research Capital LLC TRC - Defense World
Fierce Biotech Layoff Tracker 2025: Allogene cuts 28% of staff; Kyverna trims workforce by 16% - Fierce Biotech
Passage Bio Reports Q1 2025 Financial Results - TipRanks
Wedbush Adjusts Price Target on Passage Bio to $3 From $4, Maintains Outperform Rating - marketscreener.com
Passage Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Passage Bio Q1 Income From Operations USD -16.459 Million - marketscreener.com
Passage Bio (PASG) Advances Phase 1/2 Trial for PBFT02, Eyes Fut - GuruFocus
Passage BIO, Inc. SEC 10-Q Report - TradingView
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights - GlobeNewswire
Passage Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Soleno Therapeutics Announces Presentations Featuring VYKAT(TM) XR in Prader-Willi Syndrome at ISPOR 2025 - The Manila Times
Passage Bio (PASG) Expected to Announce Earnings on Tuesday - Defense World
2025 Q1 Job Market Report: Quarterly Job Postings Live Declined as Applications Spiked - BioSpace
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia
Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada
Passage Bio (NASDAQ:PASG) vs. Agenus (NASDAQ:AGEN) Critical Contrast - The AM Reporter
Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World
PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):